Applied DNA to Participate in Fireside Chat at the 34th Annual ROTH Investor Conference
March 10 2022 - 10:00AM
Business Wire
Applied DNA Sciences, Inc. (NASDAQ: APDN), a leader in
Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic
acid-based technologies, announced today that Chief Executive
Officer Dr. James A. Hayward will host a virtual fireside chat with
the Company's covering analyst, Managing Director and Senior
Research Analyst Jonathan Aschoff, on Monday, March 14, 2022, at
the 34th Annual ROTH Investor Conference.
Dr. Hayward, Beth Jantzen, chief financial officer, and Clay
Shorrock, executive director of business development, will also
host scheduled virtual one-on-one meetings with investors during
the event.
To request a one-on-one meeting with Applied DNA, please email
oneononerequests@roth.com or contact your Roth sales
representative.
34th Annual Roth Investor Conference Date: Monday, March
14, 2022 Time: 12:00 p.m. ET (9:00 a.m. ET) Webcast:
https://wsw.com/webcast/roth43/apdn/1811596
The fireside chat will be available for viewing and replay on
the Investor Relations section of the Applied DNA website at
www.adnas.com.
About Applied DNA Sciences
Applied DNA is commercializing LinearDNA™, its proprietary,
large-scale polymerase chain reaction ("PCR")-based manufacturing
platform that allows for the large-scale production of specific DNA
sequences.
The LinearDNA platform has utility in the nucleic acid-based in
vitro diagnostics and preclinical nucleic acid-based drug
development and manufacturing market. The platform is used to
manufacture DNA for customers as components of in vitro diagnostic
tests and for preclinical nucleic acid-based drug development in
the fields of adoptive cell therapies (CAR T and TCR therapies),
DNA vaccines (anti-viral and cancer), RNA therapies, clustered
regularly interspaced short palindromic repeats (CRISPR) based
therapies, and gene therapies.
The LinearDNA platform also has non-biologic applications, such
as supply chain security, anti-counterfeiting and anti-theft
technology. Key end-markets include textiles, pharmaceuticals and
nutraceuticals, and cannabis, among others.
Leveraging its deep expertise in nucleic acid-based
technologies, the Company has also established safeCircle™, a
high-throughput turnkey solution for population-scale COVID-19
testing. safeCircle is designed to look for infection within
defined populations or communities utilizing high throughput
testing methodologies that increase testing efficiencies and
provide for rapid turn-around-times.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
The Company's common stock is listed on NASDAQ under the ticker
symbol 'APDN,' and its publicly traded warrants are listed on OTC
under the ticker symbol 'APPDW.'
Applied DNA is a member of the Russell Microcap® Index.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220310005505/en/
Investor Relations: Sanjay M. Hurry, 917-733-5573,
sanjay.hurry@adnas.com Web: www.adnas.com Twitter:
@APDN
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2023 to Apr 2024